Shanghai Bio-heart Biological Technology (2185 HK)

Shanghai Bio-heart Biological Technology is an interventional cardiovascular device company that develops innovative therapies for unmet medical needs in the treatment of coronary artery disease and hypertension. Its key products include the Bioheart bioresorbable scaffolds (BRS) system, the Iberis 2nd renal denervation (RDN) product candidate, and drug-coated balloons (DCB). The company was founded in 2014 and is headquartered in Shanghai, People's Republic of China.